Immunomedics

Acquired

Next-generation ADC therapies for hard-to-treat cancers.

Morris Plains, United States · Founded 2004 · $459.0M raised

Employees
201–500
Founded
2004
Business Model
B2B
Total Funding
$459.0M
Last Round
$459.0M Private EquityMay 2020
Rounds
1
Acquired by
GileadOct 2020

About

Immunomedics was a clinical-stage biopharmaceutical company pioneering next-generation antibody-drug conjugate (ADC) technology for the targeted treatment of cancer, including triple-negative breast cancer and other solid tumors. Its lead drug, Trodelvy (sacituzumab govitecan), received FDA approval before the company was acquired by Gilead Sciences for $21 billion in 2020.

Summary

Immunomedics is a Biotechnology company based in Morris Plains, United States, founded in 2004. It has raised $459.0M in total across 1 round, most recently a $459.0M Private Equity round in May 2020. Investors include Gilead Sciences.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionAcquisition by Gilead SciencesSep 2020
$21.0B

Sign up to see all 2 rounds

Private Equity through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immunomedics on Indexed.vc
<a href="https://indexed.vc/companies/immunomedics"><img src="https://indexed.vc/api/badge/company/immunomedics" alt="Immunomedics on Indexed.vc" width="260" height="76" /></a>